Skip to main content
SpringerLink
Log in

Allogeneic Hematopoietic Stem Cell Transplantation for MDS and CMML: When and How?

  • Chapter
  • First Online:
Pathogenesis and Treatment of Leukemia

  • 439 Accesses

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative treatment in both MDS and CMML. In MDS, there is an increasing prevalence of high-risk MDS undergoing HSCT, whereas only a selected group of patients with low-risk MDS will receive standard or low-intensity HSCT for permanent disease eradication. Other than the disease risk itself, patients’ age, comorbidities, performance status, and disease risk act as limiting factors to the efficacy of HSCT in both MDS and CMML patients. Hence, not all patients are eligible for transplantation. Prognostic markers should be carefully evaluated before considering HSCT. In this chapter, we review the indications of allo-HSCT in MDS and CMML.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Platzbecker U, Kubasch AS, Homer-Bouthiette C, Prebet T. Current challenges and unmet medical needs in myelodysplastic syndromes. Leukemia. 2021;35(8):2182–98.

    PubMed  PubMed Central  Google Scholar 

  2. Abdul Hamid G, Wahab Al-Nehmi A, Shukry S. Diagnosis and classification of myelodysplastic syndrome. London: IntechOpen; 2019.

    Google Scholar 

  3. Patnaik MM, Tefferi A. Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. Am J Hematol. 2020;95(1):97–115.

    PubMed  Google Scholar 

  4. Kwon J. Diagnosis and treatment of chronic myelomonocytic leukemia. Blood Res. 2021;56(S1):S5–S16.

    PubMed  Google Scholar 

  5. Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, Van De Loosdrecht AA, et al. Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica. 2019;104(10):1935–49.

    PubMed  PubMed Central  Google Scholar 

  6. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405.

    PubMed  Google Scholar 

  7. Chien S-H, Yao M, Li C-C, Chang P-Y, Yu M-S, Huang C-E, et al. Charlson comorbidity index predicts outcomes of elderly after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome. J Formos Med Assoc. 2021;120(12):2144–52.

    PubMed  Google Scholar 

  8. Bartenstein M, Deeg HJ. Hematopoietic stem cell transplantation for MDS. Hematol Oncol Clin North Am. 2010;24(2):407–22.

    PubMed  PubMed Central  Google Scholar 

  9. Della Porta MG, Alessandrino EP, Bacigalupo A, Van Lint MT, Malcovati L, Pascutto C, et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood. 2014;123(15):2333–42.

    PubMed  Google Scholar 

  10. De Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129(13):1753–62.

    PubMed  PubMed Central  Google Scholar 

  11. Pfeilstöcker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, et al. Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016;128(7):902–10.

    PubMed  PubMed Central  Google Scholar 

  12. Kubasch AS, Platzbecker U. Patient stratification in myelodysplastic syndromes: how a puzzle may become a map. Hematology. 2020;2020(1):418–25.

    PubMed  PubMed Central  Google Scholar 

  13. Sanz GF. In MDS, is higher risk higher reward? Hematology. 2019;2019(1):381–90.

    PubMed  PubMed Central  Google Scholar 

  14. Platzbecker U. Treatment of MDS. Blood. 2019;133(10):1096–107.

    PubMed  Google Scholar 

  15. Della Porta MG, Jackson CH, Alessandrino EP, Rossi M, Bacigalupo A, Van Lint MT, et al. Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. Leukemia. 2017;31(11):2449–57.

    PubMed  PubMed Central  Google Scholar 

  16. Robin M, Porcher R, Zinke-Cerwenka W, Van Biezen A, Volin L, Mufti G, et al. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. Bone Marrow Transplant. 2017;52(2):209–15.

    PubMed  Google Scholar 

  17. Gauthier J, Damaj G, Langlois C, Robin M, Michallet M, Chevallier P, et al. Contribution of revised international prognostic scoring system cytogenetics to predict outcome after allogeneic stem cell transplantation for myelodysplastic syndromes: a study from the French society of bone marrow transplantation and cellular therapy. Transplantation. 2015;99(8):1672–80.

    PubMed  Google Scholar 

  18. Elena C, Gallì A, Such E, Meggendorfer M, Germing U, Rizzo E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128(10):1408–17.

    PubMed  PubMed Central  Google Scholar 

  19. Steensma DP. Putting it all together in CMML risk stratification. Blood. 2016;128(10):1318–9.

    PubMed  Google Scholar 

  20. Kaivers J, Schuler E, Hildebrandt B, Betz B, Rautenberg C, Haas R, et al. Improving the accuracy of prognostication in chronic myelomonocytic leukemia. Expert Rev Anticancer Ther. 2020;20(8):703–14.

    PubMed  Google Scholar 

  21. Tremblay D, Rippel N, Feld J, El Jamal SM, Mascarenhas J. Contemporary risk stratification and treatment of chronic myelomonocytic leukemia. Oncologist. 2021;26(5):406–21.

    PubMed  PubMed Central  Google Scholar 

  22. Such E, Germing U, Malcovati L, Cervera J, Kuendgen A, Della Porta MG, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121(15):3005–15.

    PubMed  Google Scholar 

  23. Robin M, de Wreede LC, Padron E, Wang J, Hazelaar S, Beelen DW, et al. Timing for allogeneic hematopoietic stem cell transplantation (HSCT) in chronic myelomonocytic leukemia (CMML): a joint study from the international MDS/MPN working group and the chronic malignancies working party of the EBMT. Blood. 2019;134(Supplement_1):4581.

    Google Scholar 

  24. Gagelmann N, Badbaran A, Beelen DW, Salit RB, Stölzel F, Rautenberg C, et al. A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation. Blood Adv. 2021;5(6):1760–9.

    PubMed  PubMed Central  Google Scholar 

  25. Kongtim P, Popat U, Jimenez A, Gaballa S, El Fakih R, Rondon G, et al. Treatment with hypomethylating agents before allogeneic stem cell transplant improves progression-free survival for patients with chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2016;22(1):47–53.

    PubMed  Google Scholar 

  26. Woo J, Choi DR, Storer BE, Yeung C, Halpern AB, Salit RB, et al. Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia. Haematologica. 2020;105(3):652–60.

    PubMed  PubMed Central  Google Scholar 

  27. Patnaik MM, Tefferi A, Garcia-Manero G. Blast-phase chronic myelomonocytic leukemia: more than just semantics. Leukemia. 2018;32(9):2093–4.

    PubMed  Google Scholar 

  28. Itonaga H, Aoki K, Aoki J, Ishikawa T, Ishiyama K, Uchida N, et al. Prognostic impact of donor source on allogeneic hematopoietic stem cell transplantation outcomes in adults with chronic myelomonocytic leukemia: a nationwide retrospective analysis in Japan. Biol Blood Marrow Transplant. 2018;24(4):840–8.

    PubMed  Google Scholar 

  29. Symeonidis A, van Biezen A, de Wreede L, Piciocchi A, Finke J, Beelen D, et al. Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol. 2015;171(2):239–46.

    PubMed  Google Scholar 

  30. Pophali P, Matin A, Mangaonkar AA, Carr R, Binder M, Al-Kali A, et al. Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. Blood Cancer J. 2020;10(11):121.

    PubMed  PubMed Central  Google Scholar 

  31. Chemnitz JM, Chakupurakal G, Bäßler M, Holtick U, Theurich S, Shimabukuro-Vornhagen A, et al. Pretransplant comorbidities maintain their impact on allogeneic stem cell transplantation outcome 5 years posttransplant: a retrospective study in a single German institution. ISRN Hematol. 2014;2014:1–7.

    Google Scholar 

  32. Kröger N. Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome. Blood. 2012;119(24):5632–9.

    PubMed  Google Scholar 

  33. McClune BL, Weisdorf DJ, Pedersen TL, Tunes Da Silva G, Tallman MS, Sierra J, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28(11):1878–87.

    PubMed  PubMed Central  Google Scholar 

  34. Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, et al. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014;5(3):238–44.

    PubMed  Google Scholar 

  35. Saber W, Horowitz MM. Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens. Hematology. 2016;2016(1):478–84.

    PubMed  PubMed Central  Google Scholar 

  36. Krishnamurthy P, Lim ZY, Nagi W, Kenyon M, Mijovic A, Ireland R, et al. Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience. Bone Marrow Transplant. 2010;45(10):1502–7.

    PubMed  Google Scholar 

  37. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.

    PubMed  Google Scholar 

  38. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–9.

    PubMed  PubMed Central  Google Scholar 

  39. Moreno Berggren D, Kjellander M, Backlund E, Engvall M, Garelius H, Lorenz F, et al. Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study. Br J Haematol. 2021;192(3):474–83.

    PubMed  Google Scholar 

  40. Eissa H, Gooley TA, Sorror ML, Nguyen F, Scott BL, Doney K, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. Biol Blood Marrow Transplant. 2011;17(6):908–15.

    PubMed  Google Scholar 

  41. Elsawy M, Sorror ML. Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2016;51(10):1283–300.

    PubMed  Google Scholar 

  42. Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG, et al. Comorbidity and disease status–based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007;25(27):4246–54.

    PubMed  Google Scholar 

  43. Zipperer E, Pelz D, Nachtkamp K, Kuendgen A, Strupp C, Gattermann N, et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica. 2009;94(5):729–32.

    PubMed  PubMed Central  Google Scholar 

  44. Sorror ML, Martin PJ, Storb RF, Bhatia S, Maziarz RT, Pulsipher MA, et al. Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. Blood. 2014;124(2):287–95.

    PubMed  PubMed Central  Google Scholar 

  45. Sorror ML. How I assess comorbidities before hematopoietic cell transplantation. Blood. 2013;121(15):2854–63.

    PubMed  PubMed Central  Google Scholar 

  46. Nampoothiri RV, Chen C, Al-Shaibani Z, Pasic I, Law A, Lam W, et al. Donor selection may predict improved survival outcomes after allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia - experience from a tertiary care centre. Blood. 2020;136(Supplement 1):23–4.

    Google Scholar 

  47. Robin M, Itzykson R. Contemporary treatment approaches to CMML - Is allogeneic HCT the only cure? Best Pract Res Clin Haematol. 2020;33(2):101138.

    PubMed  Google Scholar 

  48. Donor-matched stem cell transplant improves outcomes in older patients with high-risk MDS. Oncologist. 2021;26(S1):S15–S16.

    Google Scholar 

  49. Pidala J, Anasetti C, Kharfan-Dabaja MA, Cutler C, Sheldon A, Djulbegovic B. Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009;15(11):1415–21.

    PubMed  Google Scholar 

  50. Parmar S, De Lima M. Hematopoietic stem cell transplantation for myelodysplastic syndrome. Biol Blood Marrow Transplant. 2010;16(1):S37–44.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China

    Harinder Gill, Yammy Yung, Cherry Chu & Amber Yip

  2. Department of Medicine, Queen Mary Hospital, Hong Kong, China

    Harinder Gill

Authors
  1. Harinder Gill
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yammy Yung
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cherry Chu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Amber Yip
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Harinder Gill .

Editor information

Editors and Affiliations

  1. Department of Medicine, Queen Mary Hospital, Hongkong, Hong Kong

    Harinder Gill

  2. Department of Medicine, Queen Mary Hospital, Hongkong, Hong Kong

    Yok-Lam Kwong

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gill, H., Yung, Y., Chu, C., Yip, A. (2023). Allogeneic Hematopoietic Stem Cell Transplantation for MDS and CMML: When and How?. In: Gill, H., Kwong, YL. (eds) Pathogenesis and Treatment of Leukemia. Springer, Singapore. https://doi.org/10.1007/978-981-99-3810-0_34

Download citation

  • DOI: https://doi.org/10.1007/978-981-99-3810-0_34

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-99-3809-4

  • Online ISBN: 978-981-99-3810-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation